CC BY 4.0 · Pharmaceutical Fronts 2021; 03(02): e65-e76
DOI: 10.1055/s-0041-1735147
Original Article

Unveiling Potential Active Constituents and Pharmacological Mechanisms of Pudilanxiaoyan Oral Liquid for Anti-Coronavirus Pneumonia Using Network Pharmacology

Ying-Peng Tong
1   Institute of Natural Medicine and Health Product, School of Advanced Study, Taizhou University, Taizhou, People's Republic of China
,
Xiao-Fei Shen
2   TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China
,
Chao Li
3   Jiangsu Key Laboratory of Chinese Medicine and Characteristic Preparations for Paediatrics, Jumpcan Pharmaceutical Co., Ltd., Taizhou, People's Republic of China
,
Qi Zhou
1   Institute of Natural Medicine and Health Product, School of Advanced Study, Taizhou University, Taizhou, People's Republic of China
,
Chun-Xiao Jiang
1   Institute of Natural Medicine and Health Product, School of Advanced Study, Taizhou University, Taizhou, People's Republic of China
,
Na Li
1   Institute of Natural Medicine and Health Product, School of Advanced Study, Taizhou University, Taizhou, People's Republic of China
,
Zhen-Da Xie
1   Institute of Natural Medicine and Health Product, School of Advanced Study, Taizhou University, Taizhou, People's Republic of China
,
Zi-Ping Zhu
1   Institute of Natural Medicine and Health Product, School of Advanced Study, Taizhou University, Taizhou, People's Republic of China
,
Jian-Xin Wang
1   Institute of Natural Medicine and Health Product, School of Advanced Study, Taizhou University, Taizhou, People's Republic of China
4   Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, People's Republic of China
5   Institute of Integrative Medicine, Fudan University, Shanghai, People's Republic of China
› Author Affiliations
Funding This research was funded by the Development Project of Shanghai Peak Disciplines-Integrative Medicine (Grant No. 20180101), the Special Project of International Technology Cooperation of One Belt and One Road (Grant No. 2017C04009), and the National Key Research and Development Program of China (Grant No. 2017YFC1703903).

Abstract

The outbreak of novel coronavirus pneumonia (COVID-19), defined as a worldwide pandemic, has been a public health emergency of international concern. Pudilanxiaoyan oral liquid (PDL), an effective drug of Traditional Chinese Medicine (TCM), is considered to be an effective and alternative means for clinical prevention of COVID-19. The purpose of this study was to identify potential active constituents of PDL, and explore its underlying anti-COVID-19 mechanism using network pharmacology. Integration of target prediction (SwissTargetPrediction and STITCH database) was used to elucidate the active components of PDL. Protein–protein interaction network analyses, gene ontology, Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses, network construction, and molecular docking were applied to analyze the prospective mechanisms of the predicted target genes. Our results showed that the key active ingredients in PDL were luteolin, apigenin, esculetin, chrysin, baicalein, oroxylin A, baicalin, wogonin, cymaroside, and gallic acid. A majority of the predicted targets were mainly involved in the pathways related to viral infection, lung injury, and inflammatory responses. An in vitro study further inferred that inhibiting the activity of nuclear factor (NF)-кB signaling pathway was a key mechanism by which PDL exerted anti-COVID-19 effects. This study not only provides chemical basis and pharmacology of PDL but also the rationale for strategies to exploring future TCM for COVID-19 therapy.



Publication History

Received: 09 May 2021

Accepted: 22 June 2021

Article published online:
27 August 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany